Advertisement
Advertisement
U.S. Markets open in 4 hrs 57 mins
Advertisement
Advertisement
Advertisement
Advertisement

Legend Biotech Corporation (LEGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
41.10-0.40 (-0.96%)
At close: 04:00PM EST
41.35 +0.25 (+0.61%)
After hours: 07:50PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close41.50
Open41.00
Bid0.00 x 1200
Ask0.00 x 800
Day's Range40.04 - 42.62
52 Week Range23.41 - 58.00
Volume815,316
Avg. Volume726,734
Market Cap6.281B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.59
Earnings DateMar 16, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est64.00
  • Business Wire

    Legend Biotech to Participate in the 40th Annual J.P. Morgan Healthcare Conference

    SOMERSET, N.J., January 04, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, will virtually participate in the 40th Annual J.P. Morgan Healthcare Conference. Ying Huang, PhD, CEO and CFO of Legend Biotech, will deliver the company presentation on Tuesday, January 11, 2022 at 2:15 p.m. (Eastern Time).

  • Business Wire

    Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors

    SOMERSET, N.J., December 30, 2021--Legend Biotech appoints Dr. Ying Huang, CEO and CFO, to its board of directors.

  • Business Wire

    Legend Biotech Corporation Announces Pricing of Public Offering

    SOMERSET, N.J., December 16, 2021--Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech"), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it has priced an underwritten public offering of 7,500,000 American depositary shares ("ADSs"), each representing two ordinary shares, at a public offering price of $40.00 per ADS, for total gross proceeds of approximately $300.0 m

Advertisement
Advertisement